Login to Your Account



Other News To Note


Friday, March 18, 2011
TaiMed Biologics Inc., of Taipei, Taiwan, and Ambrilia Biopharma Inc., of Montreal, inked an agreement under which TaiMed will acquire exclusive worldwide rights to manufacture, develop and commercialize both protease inhibitor and integrase inhibitor programs for HIV. Under the terms, Ambrilia will get $250,000 up front and could receive up to an additional $7.6 million in development, regulatory and sales milestones, plus tiered royalties on worldwide product sales.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription